



Pharmacologic Agents for Treatment of Type 2 Diabetes

SCAN Formulary Drugs

Medication	2020 Formulary		2021 Formulary		Dosing & Administration	Risk for Drug- Drug Interactions *	Adverse Drug Reactions
	Tier	UM	Tier	UM			
Biguanides							
<i>metformin tabs</i>	1		1		500 – 850 mg QD - TID	Neutral	Nausea/ vomiting, GI upset, metallic taste, diarrhea, flatulence, lactic acidosis (rare)
<i>metformin er uncoated tabs 500 mg & 750 mg</i>	1		1		500 – 2000 mg daily		Nausea/ vomiting, GI upset, diarrhea, flatulence, lactic acidosis
Sulfonylureas							
<i>glimepiride</i>	1		1		1 – 8 mg daily	Moderate	Dizziness, headache, hypoglycemia, nausea, weight gain
<i>glipizide</i>	1		1		2.5 – 20 mg daily		Rash, diarrhea, dizziness, headache, diarrhea, hypoglycemia, nausea, weight gain
<i>glipizide er</i>	1		1		5 – 20 mg daily		Asthenia, headache, dizziness, rash, nausea, hypoglycemia, weight gain
<i>glipizide / metformin tabs</i>	1		1		2.5 / 500 mg BID	Moderate	Rash, diarrhea, dizziness, headache, nausea, flatulence, hypoglycemia, lactic acidosis
Thiazolidinediones & Thiazolidinedione Combination Agents							
<i>pioglitazone</i>	1		1		15 – 45 mg daily	Neutral	Anemia, edema, weight gain, headache, myalgia, bone fracture, heart failure
<i>pioglitazone / metformin</i>	2		2		15 / 500 mg – 45 / 1500mg daily		Rash, diarrhea, dizziness, headache, nausea, flatulence, hypoglycemia, lactic acidosis
<i>pioglitazone / glimepiride</i>	2	[QL]	2	[QL]	15 / 500 mg – 45 / 2550 mg daily		Anemia, edema, weight gain, headache, myalgia, dizziness, hypoglycemia, nausea

Medication	2020 Formulary		2021 Formulary		Dosing & Administration	Risk for Drug- Drug Interactions *	Adverse Drug Reactions
	Tier	UM	Tier	UM			
Alpha-Glucosidase Inhibitor							
<i>acarbose</i>	2		2		25 – 100 mg TID Administered at the start of each meal to decrease postprandial glucose peaks	Neutral	Abdominal pain, diarrhea, flatulence, elevated serum transaminases
Meglitinides							
<i>nateglinide</i>	2		2		60 – 120 mg TID before meals	Moderate	Dizziness, arthralgia, diarrhea, hypoglycemia, weight gain, increased uric acid
<i>repaglinide</i>	2		2		0.5 – 4 mg TID before meals		Hypoglycemia, arthralgia, diarrhea, weight gain
DPPIs (Dipeptidyl Peptidase-4 Inhibitors)							
JANUMET, JANUMET XR (<i>sitagliptin / metformin</i>)	3		3		100 / 2000 mg daily	Neutral	Abdominal pain, diarrhea, headache, nasopharyngitis, nausea, flatulence, lactic acidosis, pancreatitis
JANUVIA (<i>sitagliptin</i>)	3		3		100 mg daily		Abdominal pain, diarrhea, headache, nasopharyngitis, nausea, URI, pancreatitis
KOMBIGLYZE XR (<i>saxagliptin / metformin</i>)	3		3		Individualize dose; 5 / 2000 mg daily max		Nausea/ vomiting, GI upset, asthenia, diarrhea, flatulence, lactic acidosis, pancreatitis
ONGLYZA (<i>saxagliptin</i>)	3		3		2.5 – 5 mg daily		Abdominal pain, diarrhea, URI, pancreatitis, nausea, hypoglycemia

Medication	2020 Formulary		2021 Formulary		Dosing & Administration	Risk for Drug- Drug Interactions *	Adverse Drug Reactions
	Tier	UM	Tier	UM			
Insulins							
	Vial	Pen	Vial	Pen	Patient specific dosing applies	Neutral	Hypoglycemia, injection site reaction, lipodystrophy, hypokalemia
HUMALOG	3	3	3	3			
HUMALOG MIX 50/50, 75/25	3	3	3	3			
HUMULIN 70/30	3	3	3	3			
HUMULIN N	3	3	3	3			
HUMULIN R	3	-	3	-			
HUMULIN R U-500	3	3	3	3			
LANTUS (insulin glargine)	3	3	3	3			
LYUMJEV	3	3	3	3			
TOUJEO/ MAX	-	3	-	3			
GLP-1 Agonist (Glucagon-Like-Peptide-1)							
BYDUREON (exenatide er)	3	[PA]	3	[ST]	2 mg SC weekly	Neutral	Diarrhea, nausea, vomiting, constipation, headache, pancreatitis
BYETTA (exenatide)	3	[PA]	3	[ST]	5 – 10 mcg SC BID		
OZEMPIC (semaglutide)	3	[PA]	3	[ST]	0.5 – 1 mg weekly	Neutral	Diarrhea, nausea, vomiting, constipation, headache, pancreatitis
RYBELSUS (semaglutide)	-	-	3	[ST]	0.5 – 1 mg weekly	Neutral	Diarrhea, nausea, vomiting, constipation, headache, pancreatitis
TRULICITY (dulaglutide)	4	[PA]	3	[ST]	0.75 – 1.5 mg weekly	Neutral	Diarrhea, nausea, vomiting, constipation, headache, pancreatitis
VICTOZA (liraglutide)	3	[PA]	3	[ST]	0.6 mg – 1.8mg SC daily	Neutral	Diarrhea, nausea, vomiting, constipation, headache, pancreatitis

Medication	2020 Formulary		2021 Formulary		Dosing & Administration	Risk for Drug- Drug Interactions *	Adverse Drug Reactions
	Tier	UM	Tier	UM			
Amylinomimetic							
SYMLIN PEN <i>(pramlintide)</i>	5	[PA]	5	[PA]	60 mcg – 120 mcg SC prior to main meals	Neutral	Nausea, anorexia, dizziness, fatigue
SGLT2 Inhibitor (Sodium-Glucose Cotransporter 2)							
FARXIGA <i>(dapagliflozin)</i>	3	[ST]	3	[ST]	5 – 10 mg daily	Neutral	Genital mycotic infections, nasopharyngitis, UTI, back pain, increased urination, nausea
INVOKAMET <i>(canagliflozin/ metformin)</i>	3	[ST]	3	[ST]	50 / 500 – 150 / 1000 mg BID		Abdominal discomfort, constipation, diarrhea, flatulence, increased thirst, indigestion, N/V, asthenia, headache, UTI, polyuria pruritis
INVOKAMET XR <i>(canagliflozin/ metformin)</i>	3	[ST]	3	[ST]	100 / 1000 – 300 / 2000 mg daily		Abdominal discomfort, constipation, diarrhea, flatulence, increased thirst, indigestion, N/V, asthenia, headache, UTI, polyuria pruritis
INVOKANA <i>(canagliflozin)</i>	3	[ST]	3	[ST]	100 – 300 mg daily		Genital mycotic infections, UTI, thirst, increased urination, nausea
XIGDUO XR <i>(dapagliflozin/ metformin)</i>	3	[ST]	3	[ST]	5 / 500 – 10 / 2000 mg daily		Low vitamin-B12, diarrhea, headache, UTI, genital mycotic infection, nasopharyngitis

Brand-name drugs are capitalized and generic drugs are listed in the lower-case italics.

[NF] = Non-formulary [PA] = Prior Authorization [QL] = Quantity Limit [ST] = Step Therapy

* 2019 AACE/ACE Consensus Statement

Diabetes Guidelines References

SCAN Health Plan Diabetes Guidelines adapted from:

- American Diabetes Association; Standards of Medical Care in Diabetes-2020: Diabetes Care January 2020 vol. 43 no. Supplement 1 S1-S212
https://care.diabetesjournals.org/content/diacare/suppl/2019/12/20/43.Supplement_1.DC1/Standards_of_Care_2020.pdf
- Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2020 Executive Summary. *Endocrine Practice*. (2020, January). Vol. 26, No. 1, pp. 107-139.
- Drug Facts & Comparisons. (2020, August). Retrieved from www.online.factsandcomparisons.com. Wolters Kluwer Health: Deventer, The Netherlands.
- Epocrates Online (2020, August). Retrieved from: <http://online.epocrates.com>. Epocrates, Inc.: San Mateo, California.
- Reuben, D. B., Herr, K. A., Pacala, J. T., Pollock, B. G., Potter, J. F., & Semla, T. P. (2015). *Geriatrics at your fingertips*. 17th ed. (Based on AGS Guidelines.)
- Online Lexicomp (08/2020): 1100 Terex Road, Hudson, OH 44236